Evaluation of Galectin-3 as a Novel Diagnostic Biomarker in Patients with Heart Failure with Preserved Ejection Fraction
Open Access
- 1 August 2020
- journal article
- research article
- Published by Scientific Scholar in Journal of Laboratory Physicians
- Vol. 12 (02) , 126-132
Abstract
Background Heart failure is a complex cardiovascular disease with a variety of etiologies and heterogeneity. The N-terminal pro-B-type natriuretic peptide (NT-proBNP) value has limited usefulness in diagnosing heart failure with preserved ejection fraction (HFpEF). Aim The aim of the present study is to evaluate serum Galectin-3 as a diagnostic biomarker in patients with HFpEF and to compare Galectin-3 with NT-proBNP levels. Materials and Methods A cross-sectional case–control study including 63 cases of heart failure with ejection fraction ≥50% confirmed by echocardiography. NT-proBNP levels in serum were measured by electrochemiluminescence immunoassay and Galectin-3 levels in serum were measured by using an enzyme-linked-immunosorbent serologic assay kit. Results The median levels of serum Galectin-3 and NT-proBNP in patients were significantly higher than those of controls (26.59 vs. 5.27 and 927 vs. 49.3, p < 0.0001). A positive correlation was observed between serum levels of Galection-3 and NT-ProBNP (r: 0.21, p = 0.048). At cut-off values of 10.1 ng/mL and 160 pg/mL, serum Galectin-3 has 77.78% sensitivity, 95% specificity with an area under the curve (AUC) of 0.93, and serum NT-proBNP has 71.43% sensitivity, 100% specificity with an AUC of 0.87, respectively, for diagnosing HFpEF. The comparison of receiver operating characteristics curves showed that Galectin-3 has better AUC compared with NT-proBNP in diagnosing HFpEF. Serum Galectin-3 showed a positive correlation with NT-proBNP and lipid parameters. Conclusion Galectin-3 with higher sensitivity and AUC can be used as a valuable biomarker for the diagnosis of HFpEF. Simultaneous testing of both Galectin-3 and NT-proBNP can further improve the detection of patients with HFpEF.Keywords
This publication has 35 references indexed in Scilit:
- Genetic and Pharmacological Inhibition of Galectin-3 Prevents Cardiac Remodeling by Interfering With Myocardial FibrogenesisCirculation: Heart Failure, 2013
- Relationship of Plasma Galectin‐3 to Renal Function in Patients With Heart Failure: Effects of Clinical Status, Pathophysiology of Heart Failure, and Presence or Absence of Heart FailureJournal of the American Heart Association, 2012
- Galectin‐3 in Heart Failure: More Answers or More Questions?Journal of the American Heart Association, 2012
- Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fractionAnnals of Medicine, 2010
- Galectin-3, Cardiac Structure and Function, and Long-Term Mortality in Patients with Acutely Decompensated Heart FailureEuropean Journal of Heart Failure, 2010
- Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF studyClinical Research in Cardiology, 2010
- Relations of Lipid Concentrations to Heart Failure IncidenceCirculation, 2009
- The regulation of inflammation by galectin‐3Immunological Reviews, 2009
- The Imbalance Between Oxygen Demand and Supply as a Potential Mechanism in the Pathophysiology of Heart Failure: The Role of Microvascular Growth and AbnormalitiesMicrocirculation, 2003
- The Imbalance Between Oxygen Demand and Supply as a Potential Mechanism in the Pathophysiology of Heart Failure: The Role of Microvascular Growth and AbnormalitiesMicrocirculation, 2003